{"filing":{"accession_number":"0001193125-26-387310","cik":"0001841387","ticker":"CADL","company_name":"Candel Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-06","primary_document":"cadl-20260906.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-20260906.htm"},"events":[{"id":32556,"run_id":29914,"accession_number":"0001193125-26-387310","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Candel Therapeutics appointed Martine Zimmermann, PharmD, to its Board of Directors effective September 8, 2026, increasing the Board from 10 to 11 directors. Dr. Zimmermann brings 30+ years of regulatory affairs and quality expertise, directly supporting the company's planned BLA submission in Q4 2026 and commercial readiness.","company_name":"Candel Therapeutics, Inc.","ticker":"CADL","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35753,"accession_number":"0001193125-26-387310","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Martine Zimmermann, PharmD, to Candel's Board of Directors effective September 8, 2026, with the Board increasing from 10 to 11 directors. While the disclosure includes compensatory details (64,000 share option grant and $40,000 annual retainer), the principal action is her appointment to the Board. The timing is material as the company prepares for a planned BLA submission in Q4 2026, and Dr. Zimmermann's 30+ years of regulatory affairs expertise directly supports this critical milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:17:40.439156+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35754,"accession_number":"0001193125-26-387310","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Martine Zimmermann, PharmD, to Candel's Board of Directors effective September 8, 2026. The press release emphasizes her 30+ years of regulatory affairs and quality expertise as directly relevant to the company's planned BLA submission and commercial readiness. This is a material governance event—the addition of a director with specialized expertise in regulatory and quality matters at a critical inflection point for the company's lead product candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:17:40.439156+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35753,"accession_number":"0001193125-26-387310","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Martine Zimmermann, PharmD, to Candel's Board of Directors effective September 8, 2026, with the Board increasing from 10 to 11 directors. While the disclosure includes compensatory details (64,000 share option grant and $40,000 annual retainer), the principal action is her appointment to the Board. The timing is material as the company prepares for a planned BLA submission in Q4 2026, and Dr. Zimmermann's 30+ years of regulatory affairs expertise directly supports this critical milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:17:40.439156+00:00","company_name":"Candel Therapeutics, Inc.","ticker":"CADL","filing_date":"2026-09-10"},{"id":35754,"accession_number":"0001193125-26-387310","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Martine Zimmermann, PharmD, to Candel's Board of Directors effective September 8, 2026. The press release emphasizes her 30+ years of regulatory affairs and quality expertise as directly relevant to the company's planned BLA submission and commercial readiness. This is a material governance event—the addition of a director with specialized expertise in regulatory and quality matters at a critical inflection point for the company's lead product candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:17:40.439156+00:00","company_name":"Candel Therapeutics, Inc.","ticker":"CADL","filing_date":"2026-09-10"}]}